Vera Therapeutics Inc logo

VERA - Vera Therapeutics Inc News Story

$18.68 1.2  7.0%

Last Trade - 26/10/21

Sector
Healthcare
Size
Small Cap
Market Cap £266.9m
Enterprise Value £200.3m
Revenue £n/a
Position in Universe 4130th / 7273

Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy

Thu 9th September, 2021 12:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210909:nGNXC12hw&default-theme=true


SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera
Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company
focused on developing treatments for immunological diseases that improve
patients’ lives, announced today that it is scheduled to host a key opinion
leader (KOL) webinar on IgA Nephropathy (IgAN or Berger’s Disease) at 12:00
p.m. ET on Monday, September 20, 2021.

The event will feature presentations by KOLs Richard Lafayette M.D., Stanford
University Medical Center, and Jonathan Barratt, Ph.D., FRCP, University of
Leicester. Dr. Lafayette will discuss the rationale for targeting B lymphocyte
stimulator (BLyS) and a proliferation-inducing ligand (APRIL) in IgAN. Dr.
Barratt will discuss data from trials targeting BLyS and APRIL in IgAN
patients, including the Phase 2a JANUS study of atacicept, which evaluated the
efficacy and safety of atacicept in IgAN. Both KOLs will discuss the potential
for Vera’s atacicept as a treatment option. Atacicept is a recombinant
fusion protein that acts as a dual inhibitor of cytokines BLyS and APRIL,
which targets B cells and plasma cells, as well as reduces disease-causing
autoantibodies.

Dr. Lafayette and Dr. Barratt will be available to answer questions following
their formal presentations.

To register for the webinar, please click here
(https://www.globenewswire.com/Tracker?data=5By4MBa1LBVD8gOdjz-58xY9aPigYd_9WxlCgBi_mvggqiTlrV5d8yvQSrikT8VTXB2DHp2TGXbjTuVzeiCA8S2bNS9ZhanXpCzDclrw5BByM6BigrI020UAJmLm0agpvFCiOBsxgwIkMM_3sTToJg==).

KOL Biographies 
Richard Lafayette, M.D., is a professor of Medicine (Nephrology) at the
Stanford University Medical Center. Dr. Lafayette completed his medical
education at New York Medical College and went on to complete his residency at
the Long Island Jewish Medical Center, and his fellowship at Stanford
University School of Medicine. He is board-certified in Internal Medicine and
Nephrology.

Dr. Lafayette served as the Associate Chair of the Stanford University
Department of Medicine from 2002 to 2007, the Clinical Chief of Nephrology at
Stanford University from 1999 to 2012, and currently serves as the Director of
the Stanford Glomerular Disease Center since 2010. He was honored in
America’s Top Doctors, Best Doctors from 2004 to 2018, and received
America’s Top Doctors Award, Castle Connolly Medical Ltd. from 2014 to 2022.
Dr. Lafayette has been part of the following boards and professional
organizations: Editorial Board, Kidney News, American Society of Nephrology
(ASN) (2010 to 2021); Member, Glomerular Disease Advisory Committee, American
Society of Nephrology (2013 to 2017); and, Member (ex-officio), Communications
Committee, American Society of Nephrology (2015 to Present).

Jonathan Barratt, Ph.D., FRCP, leads the Renal Research Group within the
College of Life Sciences, University of Leicester. Dr. Barratt’s research is
focused on a bench to bedside approach to improving our understanding of the
pathogenesis of IgAN, a common global cause of kidney failure. He is the IgAN
Rare Disease Group lead for the United Kingdom National Registry of Rare
Kidney Diseases (RaDaR), and a member of the steering committee for the
International IgAN Network. He works closely with pharmaceutical companies
interested in new treatments for IgAN, is chief investigator for a number of
international randomized controlled Phase 2 and 3 clinical trials in IgAN, and
was a member of the U.S. Food and Drug Administration and ASN Kidney Health
Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgAN
Workgroup.

About Atacicept 
Atacicept is a novel, disease-modifying fully humanized fusion protein that is
a dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a
proliferation-inducing ligand (APRIL). These cytokines are members of the
tumor necrosis factor family that promote B-cell survival and autoantibody
production associated with immunologic diseases, including IgA nephropathy
(IgAN), also known as Berger’s disease, and systemic lupus erythematosus.
Vera believes that atacicept has the potential to be the best-in-class and the
leading B cell-targeted therapy for IgAN. Atacicept has been well tolerated
and has been used in clinical trials of more than 1,500 patients to date. In a
clinical trial of IgAN patients, data show atacicept is the first known
molecule to substantially reduce galactose-deficient immunoglobulin A
(Gd-IgA1).

About Vera 
Vera Therapeutics is a clinical-stage biotechnology company focused on
developing treatments for immunological diseases that improve patients’
lives. Vera’s lead product candidate is atacicept, a fusion protein
self-administered as a subcutaneous injection once weekly that blocks both B
lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL),
which stimulate B cells and plasma cells to produce autoantibodies
contributing to certain autoimmune diseases. In addition, Vera is evaluating
additional diseases where the reduction of autoantibodies by atacicept may
prove medically useful, including lupus nephritis, a severe renal
manifestation of systemic lupus erythematosus. For more information, please
visit www.veratx.com.

Forward-looking Statements 
Statements contained in this press release regarding matters that are not
historical facts are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements regarding, among other things, the potential of
atacicept. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as “plans,” “will”,
“anticipates,” “goal,” “potential” and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Vera’s current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results could differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which include,
without limitation, risks and uncertainties associated with Vera’s business
in general, the impact of the COVID-19 pandemic, and the other risks described
in Vera’s filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak only as of
the date on which they were made and are based on management’s assumptions
and estimates as of such date. Vera undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.

Contacts
Investor Contact: 
IR@veratx.com

Media Contact: 
Greig Communications, Inc. 
Kathy Vincent 
(310) 403-8951 
kathy@greigcommunications.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/efc6322c-d1c7-4086-b22a-57e2ead59af9)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.